These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30231723)

  • 21. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
    McKee AE; Markon AO; Chan-Tack KM; Lurie P
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication.
    Hoerger M
    Death Stud; 2016; 40(2):113-20. PubMed ID: 26313583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ethical plausibility of the 'Right To Try' laws.
    Carrieri D; Peccatori FA; Boniolo G
    Crit Rev Oncol Hematol; 2018 Feb; 122():64-71. PubMed ID: 29458791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA's Role in Ensuring Patient Safety.
    Jarow JP; Lemery S; Bugin K; Lowy N
    Ther Innov Regul Sci; 2017 Mar; 51(2):246-249. PubMed ID: 28553566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinical trial for the Food and Drug Administration's clinical trial process.
    Madden BJ
    Cancer Biother Radiopharm; 2005 Dec; 20(6):569-78. PubMed ID: 16398609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ensuring Justice in Access to Investigational Neurological Drugs.
    Kearns L; Bateman-House A; Caplan A
    Semin Neurol; 2018 Oct; 38(5):583-588. PubMed ID: 30321898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Legal and Regulatory Issues Governing Cannabis and Cannabis-Derived Products in the United States.
    Mead A
    Front Plant Sci; 2019; 10():697. PubMed ID: 31263468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies.
    Van Norman GA
    JACC Basic Transl Sci; 2018 Jun; 3(3):403-414. PubMed ID: 30062226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The FDA's new procedures for the use of investigational drugs in treatment.
    Young FE; Norris JA; Levitt JA; Nightingale SL
    JAMA; 1988 Apr; 259(15):2267-70. PubMed ID: 3280842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ethics of postmarketing observational studies of drug safety under section 505(o)(3) of the Food, Drug, and Cosmetic Act.
    Evans BJ
    Am J Law Med; 2012; 38(4):577-606. PubMed ID: 23356097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-patient expanded access: A primer for pharmacists.
    Smith AJF; Redic KA
    Am J Health Syst Pharm; 2022 Nov; 79(23):2118-2127. PubMed ID: 36056791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Right to Try" Legislation Moving Through Congress: But Drug Companies and Some Patient Groups Want Changes.
    Barlas S
    P T; 2017 Dec; 42(12):739-763. PubMed ID: 29234212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Right now, in the right way: U. S. Food and Drug Administration's expanded access program and patient rights.
    Holbein MEB; Weatherwax KJ; Gravelin M; Hutchinson R; Mashour GA
    J Clin Transl Sci; 2018 Jun; 2(3):115-117. PubMed ID: 30370061
    [No Abstract]   [Full Text] [Related]  

  • 35. Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.
    Jarow JP; Lemery S; Bugin K; Khozin S; Moscicki R
    Ther Innov Regul Sci; 2016 Nov; 50(6):705-709. PubMed ID: 27917324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Right to experimental treatment: FDA new drug approval, constitutional rights, and the public's health.
    Leonard EW
    J Law Med Ethics; 2009; 37(2):269-79. PubMed ID: 19493072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Critical Role of Medical Institutions in Expanding Access to Investigational Interventions.
    Spector-Bagdady K; Weatherwax KJ; Gravelin M; Shuman AG
    Hastings Cent Rep; 2019 Mar; 49(2):36-39. PubMed ID: 30998277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients.
    Jerome RN; Edwards TL; Boswell HC; Bernard GR; Harris PA; Pulley JM
    Acad Med; 2016 Mar; 91(3):305-9. PubMed ID: 26445080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA's compassion for desperate drug companies.
    Annas GJ
    Hastings Cent Rep; 1990; 20(1):35-7. PubMed ID: 2179165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prescribing unproven cancer drugs: physician perspectives on expanded access and right to try.
    Manley H; Sisk BA; Master Z; Scott CT
    J Law Biosci; 2022; 9(2):lsac031. PubMed ID: 36419857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.